FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/05/2026
Back to search
Official data from USPTO
NORTHX BIOLOGICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
NORTHX BIOLOGICS
ST13
US500000079380466Class
1, 5, 9, 42
Filing
79380466
Registration
7876944
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
54
Latest update
04/03/2026
Trademark type
Word
Nice classes
1, 5, 9, 42
Filing date
08/14/2023
Registration date
08/05/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/05/2025
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
SE
Examiner
REID, CAILE MAUREEN
Law office
N50
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
NorthX Biologics AB
NorthX Biologics Matfors AB
Representatives
Alexander Lazouski Lazouski IP LLC
Technical classification
Nice Classes
Class 1Class 5Class 9Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals used in industry and scienceespecially proteinsenzymes and modifications thereof
Class 5
Diagnostic preparations for pharmaceutical purposes; a full line of medicinal products; biological preparations for medical purposes; chemical preparations for medical purposes; diagnostic preparations for medical purposes; biological reagents for medical use; somatic cell therapy productsmuscle cellsblood cellsskin cells and nerve cells for medical use; pharmaceutical preparations for gene therapy usevirusviral vectorplasmid DNA material to be used in gene therapy applications for medical purposes; cell-based preparationsplasmid DNA and mRNA cell therapy for medical purposes; nucleic acid preparations being nucleic acid sequences for medical purposes; vaccines; recombinant proteins arrays for medical diagnosis purposes; therapeutic antibodies for medical purposes; microbial expressed protein arrays for medical diagnosis purposes; DNA vaccines; DNA plasmids being vaccines and pharmaceutical preparations for use in gene therapies
Class 9
Scientific apparatus and instruments being medical laboratory research instruments for controllingmeasuringacceleratingtransporting chemicals for use in biochemical and genetic research; Scientific apparatus and instrumentsapparatus and instruments being medical laboratory research instruments for use in gene therapyplasmid DNA productioncell banking and DNA sequencing
Class 42
Product research and development; new product analytical development; research and development in the pharmaceutical and biotechnology fields; research and development in the field of microorganisms and cells; research and development for the pharmaceutical industry; biochemical research and development; research services for the development of new pharmaceutical products and advanced therapy product processes; research and development of vaccines and medicines; research and development in the field of diagnostic preparations; development of new products being biological drugs and advanced therapy product processes; medical research laboratory services; research on the subject of pharmaceuticals; provision of information and data relating to medical preparation research and development; scientific research servicestechnology advisory services related to pharmaceutical research and developmentdevelopment of gene therapy productsgenetic biologic products; product research and development in the field of cell banking; product research and development in the field of plasmid DNA production; product research and development in the field of DNA sequencing; medical and scientific researchconducting clinical trials for others; medical and scientific researchconducting clinical trials for others for pharmaceutical products; scientific and medical research on cell banks.
Publications
History of USPTO decisions and trademark events.
54 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
02/13/2026
FIMP
FINAL DISPOSITION PROCESSED
02/13/2026
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/11/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/27/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
11/26/2025
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
11/26/2025
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
11/26/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
11/26/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
11/26/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
11/26/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
11/26/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/05/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/05/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
08/05/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/17/2025
PUBO
PUBLISHED FOR OPPOSITION
06/17/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/11/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/14/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/13/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/13/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/13/2025
GEAN
NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
04/24/2025
GEAP
EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
04/24/2025
EPEN
COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY
04/24/2025
CPEA
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
04/24/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/27/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/27/2025
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
03/27/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
03/22/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/04/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
03/04/2025
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
10/07/2024
GNFR
FINAL REFUSAL E-MAILED
10/07/2024
CNFR
FINAL REFUSAL WRITTEN
10/07/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/20/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/20/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/20/2024
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
08/02/2024
RFNT
REFUSAL PROCESSED BY IB
05/22/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/28/2024
RFRR
REFUSAL PROCESSED BY MPU
04/28/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/17/2024
CNRT
NON-FINAL ACTION WRITTEN
04/16/2024
DOCK
ASSIGNED TO EXAMINER
04/15/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
11/21/2023
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
11/21/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
11/21/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
11/21/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
11/21/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
11/21/2023
MAFR
APPLICATION FILING RECEIPT MAILED
10/10/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/06/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/05/2023
Continuous trademark protection
Get notified about every new filing that threatens NORTHX BIOLOGICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.